Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Walter E. Washington Convention Center

Jun 14, 2015 2:30 PM - Jun 18, 2015 6:45 PM

801 Mount Vernon Place, NW, , Washington, DC 20001-3614 , USA

DIA 2015 51st Annual Meeting: Develop. Innovate. Advance.

Full conference and one-day registrants will have access to presentation PDFs through Friday, December 18, 2015 <A href="http://www.diaglobal.org/Flagship-Meetings/DIA-Annual-Meeting/Meeting-Program/ePac-Presentations-Access.aspx">Review Presentations </A>

An Insider’s View of Cooperation Between the EMA and CDER/FDA: Question Time

Session Chair(s)

Sabine  Haubenreisser, PhD, MSc

Sabine Haubenreisser, PhD, MSc

Principal Scientific Administrator, Stakeholders and Communication Division, European Medicines Agency, Netherlands

Sandra  Kweder, MD

Sandra Kweder, MD

Principal, Drug and Biological Products , Eliquent Life Sciences, United States

New this year! Join us for this unique opportunity that includes members from EMA and CDER/FDA Leadership. This first of its kind forum will provide an opportunity for both agencies to discuss and explore at a roundtable discussion areas covered by the EMA/FDA confidentiality arrangements and discuss how both agencies contribute to global development and supervision of medicines. Experts from both agencies who have been at the forefront of EMA/CDER/FDA collaboration will explore topics such as pharmacovigilance, adaptive pathways, quality by design, and patient involvement in the development of medicines.

The audience will be invited to submit questions of general interest. Please come prepared with your questions for the EMA/CDER Question Time panel. You may submit questions and topics of interest in advance to annualmeetingprogram@diaglobal.org, and include “EMA/CDER/FDA Question Time” in the subject line.

Learning Objective : Summarize key issues discussed by EMA and CDER/FDA; Discuss the areas covered under the bilateral cooperation between EMA and FDA aimed at bringing new medicines to patients throughout the world while assuring consistent standards of quality, efficacy and safety; Identify how to engage both agencies in the development of a medicine at the same time.

Speaker(s)

Gerald  Dal Pan, MD, MHS

Panelist

Gerald Dal Pan, MD, MHS

Director, Office of Surveillance and Epidemiology, CDER, FDA, United States

Christine  Moore, PhD

Panelist

Christine Moore, PhD

Executive Director, Global External Advocacy and Standards, Organon & Co., United States

Theresa  Mullin, PhD

Panelist

Theresa Mullin, PhD

Associate Center Director - CDER, FDA, United States

Robert J. Temple, MD

Panelist

Robert J. Temple, MD

Senior Advisor for Clinical Science, OCD and Immediate Office, OND, CDER, FDA, United States

Enrica  Alteri, MD

Panelist

Enrica Alteri, MD

Head, Human Medicines Research and Development Support Division, European Medicines Agency, Netherlands

Peter Richard Arlett, MD, FFPM, FRCP

Panelist

Peter Richard Arlett, MD, FFPM, FRCP

Head Data Analytics and Methods Task Force, European Medicines Agency, Netherlands

Emer  Cooke, MBA

Panelist

Emer Cooke, MBA

Executive Director, European Medicines Agency, Netherlands

Have an account?

Ways to register

Registration override should work.

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.